United States
United States

Time filter

Source Type

News Article | November 1, 2016
Site: www.newsmaker.com.au

Surgical Stapling Device is medical device which is used to place surgical staples. Surgical staples are specialized staples used in surgery in place of sutures to close skin wounds, connect or remove parts of the bowels or lungs. Scope of the Report: This report focuses on the Surgical Stapling Devices in Global market, especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Latin America, Middle East and Africa Market Segment by Applications, can be divided into Gastrointestinal Surgery Gynecologic Surgery Thoracic Surgery Others There are 13 Chapters to deeply display the global Surgical Stapling Devices market. Chapter 2, to analyze the top manufacturers of Surgical Stapling Devices, with sales, revenue, and price of Surgical Stapling Devices, in 2015 and 2016; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016; Chapter 4, to show the global market by regions, with sales, revenue and market share of Surgical Stapling Devices, for each region, from 2011 to 2016; Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions; Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016; Chapter 11, Surgical Stapling Devices market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021; Chapter 12 and 13, to describe Surgical Stapling Devices sales channel, distributors, traders, dealers, appendix and data source. Global Surgical Stapling Devices Market by Manufacturers, Regions, Type and Application, Forecast to 2021 1 Market Overview 1.1 Surgical Stapling Devices Introduction 1.2 Market Analysis by Type 1.2.1 Straight Surgical Stapling Devices 1.2.2 Curved Surgical Stapling Devices 1.2.3 Circular Surgical Stapling Devices 1.3 Market Analysis by Applications 1.3.1 Gastrointestinal Surgery 1.3.2 Gynecologic Surgery 1.3.3 Thoracic Surgery 1.4 Market Analysis by Regions 1.4.1 North America (USA, Canada and Mexico) 1.4.1.1 USA 1.4.1.2 Canada 1.4.1.3 Mexico 1.4.2 Europe (Germany, France, UK, Russia and Italy) 1.4.2.1 Germany 1.4.2.2 France 1.4.2.3 UK 1.4.2.4 Russia 1.4.2.5 Italy 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 1.4.3.1 China 1.4.3.2 Japan 1.4.3.3 Korea 1.4.3.4 India 1.4.3.5 Southeast Asia 1.4.4 Latin America, Middle East and Africa 1.4.4.1 Brazil 1.4.4.2 Egypt 1.4.4.3 Saudi Arabia 1.4.4.4 South Africa 1.4.4.5 Nigeria 1.5 Market Dynamics 1.5.1 Market Opportunities 1.5.2 Market Risk 1.5.3 Market Driving Force 2 Manufacturers Profiles 2.1 J&J (Ethicon) 2.1.1 Business Overview 2.1.2 Surgical Stapling Devices Type and Applications 2.1.2.1 Type 1 2.1.2.2 Type 2 2.1.3 J&J (Ethicon) Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.2 Medtronic 2.2.1 Business Overview 2.2.2 Surgical Stapling Devices Type and Applications 2.2.2.1 Type 1 2.2.2.2 Type 2 2.2.3 Medtronic Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.3 B.Braun 2.3.1 Business Overview 2.3.2 Surgical Stapling Devices Type and Applications 2.3.2.1 Type 1 2.3.2.2 Type 2 2.3.3 B.Braun Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.4 BD 2.4.1 Business Overview 2.4.2 Surgical Stapling Devices Type and Applications 2.4.2.1 Type 1 2.4.2.2 Type 2 2.4.3 BD Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.5 Conmed 2.5.1 Business Overview 2.5.2 Surgical Stapling Devices Type and Applications 2.5.2.1 Type 1 2.5.2.2 Type 2 2.5.3 Conmed Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.6 Grena 2.6.1 Business Overview 2.6.2 Surgical Stapling Devices Type and Applications 2.6.2.1 Type 1 2.6.2.2 Type 2 2.6.3 Grena Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.7 Frankenman 2.7.1 Business Overview 2.7.2 Surgical Stapling Devices Type and Applications 2.7.2.1 Type 1 2.7.2.2 Type 2 2.7.3 Frankenman Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.8 Purple surgical 2.8.1 Business Overview 2.8.2 Surgical Stapling Devices Type and Applications 2.8.2.1 Type 1 2.8.2.2 Type 2 2.8.3 Purple surgical Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.9 Kangdi 2.9.1 Business Overview 2.9.2 Surgical Stapling Devices Type and Applications 2.9.2.1 Type 1 2.9.2.2 Type 2 2.9.3 Kangdi Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.10 Reach 2.10.1 Business Overview 2.10.2 Surgical Stapling Devices Type and Applications 2.10.2.1 Type 1 2.10.2.2 Type 2 2.10.3 Reach Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.11 Dextera Surgical 2.11.1 Business Overview 2.11.2 Surgical Stapling Devices Type and Applications 2.11.2.1 Type 1 2.11.2.2 Type 2 2.11.3 Dextera Surgical Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 2.12 Medizintechnik 2.12.1 Business Overview 2.12.2 Surgical Stapling Devices Type and Applications 2.12.2.1 Type 1 2.12.2.2 Type 2 2.12.3 Medizintechnik Surgical Stapling Devices Sales, Price, Revenue, Gross Margin and Market Share 3 Global Surgical Stapling Devices Market Competition, by Manufacturer 3.1 Global Surgical Stapling Devices Sales and Market Share by Manufacturer 3.2 Global Surgical Stapling Devices Revenue and Market Share by Manufacturer 3.3 Market Concentration Rate 3.3.1 Top 3 Surgical Stapling Devices Manufacturer Market Share 3.3.2 Top 6 Surgical Stapling Devices Manufacturer Market Share 3.4 Market Competition Trend 4 Global Surgical Stapling Devices Market Analysis by Regions 4.1 Global Surgical Stapling Devices Sales, Revenue and Market Share by Regions 4.1.1 Global Surgical Stapling Devices Sales by Regions (2011-2016) 4.1.2 Global Surgical Stapling Devices Revenue by Regions (2011-2016) 4.2 North America Surgical Stapling Devices Sales and Growth (2011-2016) 4.3 Europe Surgical Stapling Devices Sales and Growth (2011-2016) 4.4 Asia-Pacific Surgical Stapling Devices Sales and Growth (2011-2016) 4.5 Latin America Surgical Stapling Devices Sales and Growth (2011-2016) 4.6 Middle East and Africa Surgical Stapling Devices Sales and Growth (2011-2016) 5 North America Surgical Stapling Devices by Countries 5.1 North America Surgical Stapling Devices Sales, Revenue and Market Share by Countries 5.1.1 North America Surgical Stapling Devices Sales by Countries (2011-2016) 5.1.2 North America Surgical Stapling Devices Revenue by Countries (2011-2016) 5.2 USA Surgical Stapling Devices Sales and Growth (2011-2016) 5.3 Canada Surgical Stapling Devices Sales and Growth (2011-2016) 5.4 Mexico Surgical Stapling Devices Sales and Growth (2011-2016) 6 Europe Surgical Stapling Devices by Countries 6.1 Europe Surgical Stapling Devices Sales, Revenue and Market Share by Countries 6.1.1 Europe Surgical Stapling Devices Sales by Countries (2011-2016) 6.1.2 Europe Surgical Stapling Devices Revenue by Countries (2011-2016) 6.2 Germany Surgical Stapling Devices Sales and Growth (2011-2016) 6.3 UK Surgical Stapling Devices Sales and Growth (2011-2016) 6.4 France Surgical Stapling Devices Sales and Growth (2011-2016) 6.5 Russia Surgical Stapling Devices Sales and Growth (2011-2016) 6.6 Italy Surgical Stapling Devices Sales and Growth (2011-2016) 7 Asia-Pacific Surgical Stapling Devices by Countries 7.1 Asia-Pacific Surgical Stapling Devices Sales, Revenue and Market Share by Countries 7.1.1 Asia-Pacific Surgical Stapling Devices Sales by Countries (2011-2016) 7.1.2 Asia-Pacific Surgical Stapling Devices Revenue by Countries (2011-2016) 7.2 China Surgical Stapling Devices Sales and Growth (2011-2016) 7.3 Japan Surgical Stapling Devices Sales and Growth (2011-2016) 7.4 Korea Surgical Stapling Devices Sales and Growth (2011-2016) 7.5 India Surgical Stapling Devices Sales and Growth (2011-2016) 7.6 Southeast Asia Surgical Stapling Devices Sales and Growth (2011-2016) 8 Latin America, Middle East and Africa Surgical Stapling Devices by Countries 8.1 Latin America, Middle East and Africa Surgical Stapling Devices Sales, Revenue and Market Share by Countries 8.1.1 Latin America, Middle East and Africa Surgical Stapling Devices Sales by Countries (2011-2016) 8.1.2 Latin America, Middle East and Africa Surgical Stapling Devices Revenue by Countries (2011-2016) 8.2 Brazil Surgical Stapling Devices Sales and Growth (2011-2016) 8.3 Saudi Arabia Surgical Stapling Devices Sales and Growth (2011-2016) 8.4 Egypt Surgical Stapling Devices Sales and Growth (2011-2016) 8.5 Nigeria Surgical Stapling Devices Sales and Growth (2011-2016) 8.6 South Africa Surgical Stapling Devices Sales and Growth (2011-2016) 9 Surgical Stapling Devices Market Segment by Type 9.1 Global Surgical Stapling Devices Sales, Revenue and Market Share by Type (2011-2016) 9.1.1 Global Surgical Stapling Devices Sales and Market Share by Type (2011-2016) 9.1.2 Global Surgical Stapling Devices Revenue and Market Share by Type (2011-2016) 9.2 Straight Surgical Stapling Devices Sales Growth and Price 9.2.1 Global Straight Surgical Stapling Devices Sales Growth (2011-2016) 9.2.2 Global Straight Surgical Stapling Devices Price (2011-2016) 9.3 Curved Surgical Stapling Devices Sales Growth and Price 9.3.1 Global Curved Surgical Stapling Devices Sales Growth (2011-2016) 9.3.2 Global Curved Surgical Stapling Devices Price (2011-2016) 9.4 Circular Surgical Stapling Devices Sales Growth and Price 9.4.1 Global Circular Surgical Stapling Devices Sales Growth (2011-2016) 9.4.2 Global Circular Surgical Stapling Devices Price (2011-2016) 10 Surgical Stapling Devices Market Segment by Application 10.1 Global Surgical Stapling Devices Sales Market Share by Application (2011-2016) 10.2 Gastrointestinal Surgery Sales Growth (2011-2016) 10.3 Gynecologic Surgery Sales Growth (2011-2016) 10.4 Thoracic Surgery Sales Growth (2011-2016) 10.5 Others Sales Growth (2011-2016) 11 Surgical Stapling Devices Market Forecast (2016-2021) 11.1 Global Surgical Stapling Devices Sales, Revenue and Growth Rate (2016-2021) 11.2 Surgical Stapling Devices Market Forecast by Regions (2016-2021) 11.3 Surgical Stapling Devices Market Forecast by Type (2016-2021) 11.4 Surgical Stapling Devices Market Forecast by Application (2016-2021) 12 Sales Channel, Distributors, Traders and Dealers 12.1 Sales Channel 12.1.1 Direct Marketing 12.1.2 Indirect Marketing 12.1.3 Marketing Channel Future Trend 12.2 Distributors, Traders and Dealers 13 Appendix 13.1 Methodology 13.2 Analyst Introduction 13.3 Data SourceList of Tables and Figures Get It Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=717174


Research and Markets has announced the addition of the "Global Hybrid Operating Suites Market Analysis and Trends - Device, Application - Forecast to 2025" report to their offering. Some of the prominent trends that the market is witnessing include recent development of trans-catheter treatment to perform hybrid approaches, 3D hybrid operating room will raise, the growth towards minimally invasive procedures and Hybrid Imaging Systems for diagnosis and staging of human disease. Based on device the market is categorized into Intraoperative diagnostic devices, Operating Room Communication Systems, Operating Room Lights, Operating Tables, Surgical Booms, Surgical Imaging Displays, Surgical Microscope, Endoscopic Hd Surgical Camera System, Anesthesia machine and Surgical carts and storage systems. An intraoperative diagnostic device is further segmented into Magnetic Resonance Imaging (MRI), Computer Tomography, Computer Assisted Robotic Surgery, C-Arm X-Ray, Infra Red Imaging Systems and 3D Ultrasound. The Operating Room Communication Systems is further segmented into Audio Visual and Operating Room Integration System. The Operating Room Lights are again segmented into Dimmable Lights, Led Lighting and Halogens. Operating Tables segment is divided into Mobile Operating Tables and Stationary Operating Tables. The Surgical Imaging Displays segment is further divided into HD Surgical Display and UHD Surgical Display. Depending on the application the market is segmented by Diagnostic Imaging and Therapeutic. The Diagnostic Imaging segment is further divided into Fluoroscopy, Digital Subtraction Angiography, Three-Dimensional (3d) C-Arm Computed Tomography and Rotational Angiography System. Therapeutic is sub divided into Cardiovascular, Neurosurgery, Thoracic Surgery, Biopsy, Orthopedic Surgeries, Laparoscopic Surgeries, Emergency Care and Other Surgeries. This industry report analyzes the global markets for Hybrid Operating Suites across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. 3 Market Overview 3.1 Current Trends 3.1.1 Recent development of trans-catheter treatment to perform hybrid approaches 3.1.2 3D hybrid operating room will rise 3.1.3 The growth towards minimally invasive procedures 3.1.4 Hybrid Imaging Systems for diagnosis and staging of human disease 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness 9 Leading Companies 9.1 Brainlab AG 9.2 Barco Nv 9.3 Cook Medical 9.4 Beacon Health System 9.5 KARL STORZ GmbH & Co. KG 9.6 Banyan Medical Systems 9.7 ImageStream Medical 9.8 GE Healthcare 9.9 Mediflex Surgical Products 9.10 Foreseeson Technology Inc 9.11 FSN Medical Technologies 9.12 Maquet Holding B.V. & Co. KG 9.13 Philips Healthcare 9.14 Olympus Corporation 9.15 Skytron LLC 9.16 Steris Corporation 9.17 Trumpf Gmbh + Co. Kg 9.18 Toshiba Medical Systems Corp 9.19 Philips Healthcare 9.20 NEC Display Solutions of America 9.21 Draeger Medical Inc. 9.22 VTS Medical 9.23 Affymetrix, Inc. 9.24 Bristol-Myers Squibb Company For more information about this report visit http://www.researchandmarkets.com/research/bntz5r/global_hybrid


News Article | February 21, 2017
Site: globenewswire.com

ALAMEDA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $2,031,250 through the early exercise of 625,000 common stock purchase warrants.  Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued during August 2016 through a private placement of 3,246,153 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.  The exercise transactions were negotiated with certain warrant holders as a means of raising additional near term working capital. In consideration for the early exercise of the warrants, one warrant holder received one new warrant with an exercise price of $3.25 for every two warrants exercised, while the other warrant holders received one new warrant with an exercise price of $5.50 for each warrant exercised. Following the exercise of the warrants, there are 29,361,616 shares of common stock outstanding and an aggregate of 3,033,653 warrants outstanding, including both warrants issued during August 2016 and the new warrants, with exercise prices ranging from $3.25 to $5.50. The proceeds from the early warrant exercise will be used for general working capital purposes to strengthen OncoCyte’s balance sheet, which reflected cash on hand of approximately $10.2 million as of December 31, 2016. “The early exercise of warrants by some of our largest shareholders provides a strong vote of confidence in OncoCyte and our progress towards the development of our innovative, non-invasive tests for the early detection of cancer. The capital provided to us increases our resources as we prepare for CLIA certification of our laboratory and the hiring of our launch team,” said William Annett, President & CEO.  “The warrant exercise and commensurate purchase of shares results in BioTime, Inc.’s ownership of our company falling below 50%. This is an important step in OncoCyte’s evolution into an independent company.” OncoCyte has completed sample collection for the 300-patient study of its lung cancer diagnostic test and now has all of the benign and malignant samples necessary to complete the study. Processing of the samples has been completed and an analysis of the results is underway.  The Company expects to complete the study and announce the results in March. As the analysis of the samples is carried out, OncoCyte is continuing to work on completing the steps necessary to obtain CLIA certification of a diagnostic laboratory. OncoCyte plans to apply for CLIA certification of the lab subsequent to the completion of its current lung cancer test study. After CLIA certification of the laboratory, OncoCyte will conduct a clinical validation study of its lung cancer diagnostic test using the finalized processing algorithm and operational procedures on a new set of a minimum of 300 blinded patient blood samples. “Completion of sample collection, processing the samples and analyzing the results are three key elements in developing our lung cancer diagnostics test,” said Mr. Annett. “If the results of the 300 sample study are favorable, our next steps will be to begin the final clinical validation study and finalize our commercialization plans.” The development of the test builds on research that began a decade ago at the Wistar Institute and has proceeded at OncoCyte and in collaboration with several key opinion leaders in the field of lung cancer diagnosis. OncoCyte recently announced that its abstract on interim data from its current lung cancer diagnostic test study has been selected for presentation in a poster discussion session at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C.  The discussion will be led by Dr. Anil Vachani, an Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center.  The analysis “Multi-Gene Classifier for the Diagnosis of Benign Versus Malignant Pulmonary Nodules” will be discussed in the “Pulmonary Nodules and Thoracic Surgery: Working Across the Aisle” session to take place at 2:15 p.m. on Monday, May 22nd. OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncocyte.com. This press release contains forward-looking statements.  Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) are forward-looking statements. These statements include those pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients ’use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in “Risk Factors” found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as may be required by law.


News Article | February 21, 2017
Site: globenewswire.com

ALAMEDA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $2,031,250 through the early exercise of 625,000 common stock purchase warrants.  Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued during August 2016 through a private placement of 3,246,153 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.  The exercise transactions were negotiated with certain warrant holders as a means of raising additional near term working capital. In consideration for the early exercise of the warrants, one warrant holder received one new warrant with an exercise price of $3.25 for every two warrants exercised, while the other warrant holders received one new warrant with an exercise price of $5.50 for each warrant exercised. Following the exercise of the warrants, there are 29,361,616 shares of common stock outstanding and an aggregate of 3,033,653 warrants outstanding, including both warrants issued during August 2016 and the new warrants, with exercise prices ranging from $3.25 to $5.50. The proceeds from the early warrant exercise will be used for general working capital purposes to strengthen OncoCyte’s balance sheet, which reflected cash on hand of approximately $10.2 million as of December 31, 2016. “The early exercise of warrants by some of our largest shareholders provides a strong vote of confidence in OncoCyte and our progress towards the development of our innovative, non-invasive tests for the early detection of cancer. The capital provided to us increases our resources as we prepare for CLIA certification of our laboratory and the hiring of our launch team,” said William Annett, President & CEO.  “The warrant exercise and commensurate purchase of shares results in BioTime, Inc.’s ownership of our company falling below 50%. This is an important step in OncoCyte’s evolution into an independent company.” OncoCyte has completed sample collection for the 300-patient study of its lung cancer diagnostic test and now has all of the benign and malignant samples necessary to complete the study. Processing of the samples has been completed and an analysis of the results is underway.  The Company expects to complete the study and announce the results in March. As the analysis of the samples is carried out, OncoCyte is continuing to work on completing the steps necessary to obtain CLIA certification of a diagnostic laboratory. OncoCyte plans to apply for CLIA certification of the lab subsequent to the completion of its current lung cancer test study. After CLIA certification of the laboratory, OncoCyte will conduct a clinical validation study of its lung cancer diagnostic test using the finalized processing algorithm and operational procedures on a new set of a minimum of 300 blinded patient blood samples. “Completion of sample collection, processing the samples and analyzing the results are three key elements in developing our lung cancer diagnostics test,” said Mr. Annett. “If the results of the 300 sample study are favorable, our next steps will be to begin the final clinical validation study and finalize our commercialization plans.” The development of the test builds on research that began a decade ago at the Wistar Institute and has proceeded at OncoCyte and in collaboration with several key opinion leaders in the field of lung cancer diagnosis. OncoCyte recently announced that its abstract on interim data from its current lung cancer diagnostic test study has been selected for presentation in a poster discussion session at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C.  The discussion will be led by Dr. Anil Vachani, an Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center.  The analysis “Multi-Gene Classifier for the Diagnosis of Benign Versus Malignant Pulmonary Nodules” will be discussed in the “Pulmonary Nodules and Thoracic Surgery: Working Across the Aisle” session to take place at 2:15 p.m. on Monday, May 22nd. OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncocyte.com. This press release contains forward-looking statements.  Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) are forward-looking statements. These statements include those pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients ’use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in “Risk Factors” found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as may be required by law.


News Article | November 24, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Global Aerospace Insurance Market 2016-2020” new report to its research database. The report spread across 59 pages with table and figures in it. The research analysts forecast the global aerospace insurance market to decline at a CAGR of -0.37% during the period 2016-2020. About Aerospace Insurance Aerospace insurance, as covered in this report, encompasses the insurance policies designed for airlines, airports and their operations, as well as other aviation service providers. Aerospace is one of the biggest sectors worldwide responsible for the conveyance of a growing number of passengers and cargo. Covered in this report The report covers the present scenario and the growth prospects of the global aerospace insurance market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of aerospace insurance. The market is divided into the following segments based on geography: - Americas - APAC - EMEA Research report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-aerospace-insurance-market-2016-2020/ Key vendors - Allianz - American International Group (AIG) - Aon - Hallmark Aerospace Insurance Managers - Marsh - Old Republic Aerospace Other prominent vendors - Arthur J. Gallagher & Co - Avion Insurance - Global Aerospace - Hiscox London Market - Wells Fargo - Willis Towers Watson - XL Catlin Market driver - Establishment of new airports - For a full, detailed list, view our report Market challenge - Lack of awareness and delayed services - For a full, detailed list, view our report Market trend - Reduced insurance claims and increased underwriting capacity - For a full, detailed list, view our report Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | February 21, 2017
Site: globenewswire.com

ALAMEDA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $2,031,250 through the early exercise of 625,000 common stock purchase warrants.  Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued during August 2016 through a private placement of 3,246,153 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.  The exercise transactions were negotiated with certain warrant holders as a means of raising additional near term working capital. In consideration for the early exercise of the warrants, one warrant holder received one new warrant with an exercise price of $3.25 for every two warrants exercised, while the other warrant holders received one new warrant with an exercise price of $5.50 for each warrant exercised. Following the exercise of the warrants, there are 29,361,616 shares of common stock outstanding and an aggregate of 3,033,653 warrants outstanding, including both warrants issued during August 2016 and the new warrants, with exercise prices ranging from $3.25 to $5.50. The proceeds from the early warrant exercise will be used for general working capital purposes to strengthen OncoCyte’s balance sheet, which reflected cash on hand of approximately $10.2 million as of December 31, 2016. “The early exercise of warrants by some of our largest shareholders provides a strong vote of confidence in OncoCyte and our progress towards the development of our innovative, non-invasive tests for the early detection of cancer. The capital provided to us increases our resources as we prepare for CLIA certification of our laboratory and the hiring of our launch team,” said William Annett, President & CEO.  “The warrant exercise and commensurate purchase of shares results in BioTime, Inc.’s ownership of our company falling below 50%. This is an important step in OncoCyte’s evolution into an independent company.” OncoCyte has completed sample collection for the 300-patient study of its lung cancer diagnostic test and now has all of the benign and malignant samples necessary to complete the study. Processing of the samples has been completed and an analysis of the results is underway.  The Company expects to complete the study and announce the results in March. As the analysis of the samples is carried out, OncoCyte is continuing to work on completing the steps necessary to obtain CLIA certification of a diagnostic laboratory. OncoCyte plans to apply for CLIA certification of the lab subsequent to the completion of its current lung cancer test study. After CLIA certification of the laboratory, OncoCyte will conduct a clinical validation study of its lung cancer diagnostic test using the finalized processing algorithm and operational procedures on a new set of a minimum of 300 blinded patient blood samples. “Completion of sample collection, processing the samples and analyzing the results are three key elements in developing our lung cancer diagnostics test,” said Mr. Annett. “If the results of the 300 sample study are favorable, our next steps will be to begin the final clinical validation study and finalize our commercialization plans.” The development of the test builds on research that began a decade ago at the Wistar Institute and has proceeded at OncoCyte and in collaboration with several key opinion leaders in the field of lung cancer diagnosis. OncoCyte recently announced that its abstract on interim data from its current lung cancer diagnostic test study has been selected for presentation in a poster discussion session at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C.  The discussion will be led by Dr. Anil Vachani, an Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center.  The analysis “Multi-Gene Classifier for the Diagnosis of Benign Versus Malignant Pulmonary Nodules” will be discussed in the “Pulmonary Nodules and Thoracic Surgery: Working Across the Aisle” session to take place at 2:15 p.m. on Monday, May 22nd. OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncocyte.com. This press release contains forward-looking statements.  Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) are forward-looking statements. These statements include those pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients ’use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in “Risk Factors” found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as may be required by law.


— The analysts forecast the global automotive ASHR market to grow at a CAGR of 8.74% during the period 2016-2020. AHSR were first mandated for use in racing cars and was known as the head and neck support (HANS) device. Many car racing motorsports, including the National Association for Stock Car Auto Racing (NASCAR), have now made HANS a compulsory feature to be added in sports cars participating in its events. The HANS device is used to maintain the relative position of the head to the body during a rear-impact collision. In addition, the device transfers the crash energy to stronger regions of the victim's body, including the chest and torso. For more information or any query mail at sales@wiseguyreports.com The report covers the present scenario and the growth prospects of the global automotive ASHR market for 2016-2020. To calculate the market size, the report considers a combination of top-down and bottom-up approaches, wherein our in-house databases have been used to arrive at the global ASHR market size. The market is divided into the following segments based on geography: The report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Market driver • Growing demand for safety solutions to drive ASHR adoption • For a full, detailed list, view our report Market challenge • Difficulty in fitting custom headrests with factory-fitted non-modular ASHR systems • For a full, detailed list, view our report • Adoption of LiDAR technology in ASHR to produce smart headrest systems • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? PART 04: Introduction • Key market highlights • Automotive seating systems: A look back in history • ASHR: Intermediate stage to smart seats • Smart seats: The future? PART 05: Market landscape • Market overview • Testing and evaluation of ASHR • Market size and forecast: ASHR market • Product life cycle (PLC): ASHR • A few regulatory frameworks governing ASHR • Five forces analysis PART 09: Market trends: The next stage of ASHR evolution • Central concept behind evolution of ASHR systems: Informative and algorithmic independence • Working mechanism trends For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


News Article | November 22, 2016
Site: marketersmedia.com

Market research future has a cooked research report on global platelet agitator market. The global market for platelet agitator is expected to grow by 4.1% CAGR during the period 2016 to 2027 from USD 296 million in 2015. The global platelet agitator market has been evaluated as steadily growing market and expected to continue the same way in the near future. There has been a tremendous growth in the investments in the biomedical sector in the recent time. The surprising fact is that the investment that is made in the sector is more by the Asian countries such as China, South Korea, India, Japan and others. Many of the Asian countries and African countries are still in their development phase. Increasing technological advancements and development of the infrastructure in such countries will help boost the overall biomedical market which will ultimately help in the growth of the platelet agitator market. • The platelet agitator global market and is expected to reach $502 million by 2027. • Flatbed agitator holds the largest share of 64.9% of the platelet agitator • North America holds the largest market share of 36.6% of market and is anticipated to reach $170.2 million by the end of forecast period. • Globally, Asia-Pacific the fastest growing region and expected to grow at the rate of 4.6% during the forecast period. • Medium sized agitator holds the largest market share in 2015, and expected to continue the similar growth throughout the forecast period. In the coming years, the platelet agitator market will continue to grow steadily. There has been rise in investments in the biomedical sector across the world especially in the Asian countries including the developing nations. Besides that, there has been rise in the disorders that drastically reduce the number of platelets. North America is the region leading the market of platelet agitators. However, the market is growing rapidly in the Asia-Pacific region where India being the major country having huge number of population. Taste the market data and market information presented through more than 50 market data tables and figures spread in 93 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Platelet Agitator Market Research Report- Global Forecast To 2027” • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the platelet agitator market. • To provide insights about factors affecting the market growth. • To analyze the platelet agitator market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by type, by capacity, by end user and its sub-segments. • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global platelet agitator market. 3 Market Dynamics 3.1 Drivers 3.1.1 Growing Investments in the Biomedical Industry 3.1.2 Increasing Prevalence of Disorders Causing Reduction of Platelets 3.1.3 Technological Advancements in the Platelet Agitator Equipment 3.2 Restraints 3.2.1 Rotational motion is harmful for the viability of the platelets 3.3 Opportunities 3.4 Macroeconomic Indicators Global Pleurisy Market Information, by diagnosis devices (Thoracoscopy, Video-Assisted Thoracic Surgery, Imaging devices, Blood Test and others), by end user (Hospital, Clinics, Diagnostic Laboratories and others) - Forecast to 2022 At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com/reports/platelet-agitator-market-research-report-global-forecast-to-2027


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Robotic Pharmacy Prescription Dispensing Systems Market 2017-2021" report to their offering. The global robotic pharmacy prescription systems market to grow at a CAGR of 5.16% during the period 2017-2021. The report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Vendors are providing technicians with operational guidance and personalized technical support 24/7. In addition, with the support package, vendors are offering automated systems updated with the latest software and drug database for both new installation and leased systems. Therefore, vendors are offering maintenance and post-purchase services to end-users to retain their customer base and remain competitive in the market. According to the report, the automation of prescription dispensing is becoming increasingly essential because of the deficit in the quality staff in pharmacies. This has led to increased adoption of pharmacy automation systems to reduce dispensing errors, improvement in the dispensing process, optimization of space utilization in pharmacies, and delivery of more patient-centric services. For more information about this report visit http://www.researchandmarkets.com/research/8lk9nm/global_robotic


— Governance, risk, and compliance constitute three essential dimensions for an organization as they assist in addressing the business objectives. The management of a company implements structural policies and reforms to ensure corporate governance in an organization. The risk management policies identify and manage different risks, including operational risks, financial risks, and fraud. Compliance encompasses policies, procedures, and adherence to rules and regulations framed by regulatory bodies in a given region. Publisher's analysts forecast the global GRC platform market to grow at a CAGR of 13.51% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global GRC platform market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of GRC platform worldwide. The market is divided into the following segments based on geography: -Americas -APAC -EMEA Publisher's report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Get Sample of the Report at: http://www.reportsweb.com/inquiry&RW0001502498/sample . Market driver -Increased need to comply with regulatory requirements -For a full, detailed list, view our report Market challenge -System integration issues for cloud-based and on-premises GRC solutions -For a full, detailed list, view our report Market trend -Rise of cloud-based e-discovery solution market -For a full, detailed list, view our report PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Economic overview of market PART 06: Market landscape PART 07: Market segmentation by deployment models PART 08: Geographical segmentation PART 09: Market drivers PART 10: Impact of drivers PART 11: Market challenges PART 12: Impact of drivers and challenges PART 13: Market trends PART 14: Five forces analysis PART 15: Vendor landscape PART 16: Key vendor profiles PART 17: Other prominent vendors PART 18: Appendix For more information, please visit http://www.reportsweb.com/global-governance-risk-and-compliance-platform-market-2017-2021

Loading Thoracic Surgery collaborators
Loading Thoracic Surgery collaborators